Fmc Stock Earnings Reports

FMC reported Q1 2026 results slightly above guidance driven by FX tailwinds, volume growth in branded products and cost improvements. Management reiterated four operational priorities for 2026: target ~$1 billion of debt reduction (primarily via sale of the India commercial business, licensing deals, noncore asset sales and real estate transactions), improve competitiveness of the non-diamide core by shifting production to lower-cost Asian sources (target completion Q1 2027), manage the Rynaxypyr post-patent transition (aiming for flat branded earnings while accepting lower prices and pursuing mix improvements), and scale new active ingredients (Isoflex, fluindapyr, Dodhylex), which doubled sales year-over-year in Q1 and recently secured Isoflex active approval in the EU. Q1 sales were $762M (-4% YoY; +1% like-for-like ex-India); adjusted EBITDA was $72M (above guidance) and adjusted loss per share was $0.23. Guidance: Q2 revenue $850M–$900M; full-year 2026 unchanged at $3.6B–$3.8B sales, adjusted EBITDA $670M–$730M, adjusted EPS $1.63–$1.89. Management expects H1 2026 to be an earnings trough with sequential improvement in H2 and more meaningful benefits in 2027 as new products scale and cost actions take hold. The company continues active processes to monetize assets (India sale in late stage, licensing discussions, real estate and noncore molecule sales) with ~70% (~$700M) line-of-sight toward the $1B debt-paydown target. Leverage remains elevated (net debt ~ $4.1B; net debt / TTM EBITDA ~5.2x), but FMC completed a revolver amendment (now fully secured) and added a secured leverage covenant; management plans to use asset-sale and licensing proceeds to reduce debt and may issue a secured high-yield bond to refinance ~$500M maturing notes. Key near-term risks include tariff/timing uncertainty related to the Iran conflict, input cost volatility (energy, transportation, petrochemicals), and competitive pressure from generics, particularly in LatAm and Asia.